EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Immunogenicity and real-world effectiveness of COVID-19 vaccines in Lebanon: Insights from primary and booster schemes, variants, infections, and hospitalization

Rima Moghnieh iD, Wajdi Haddad, Nayla Jbeily, Salam El-Hassan, Shadi Eid, Hicham Baba, Marilyne Sily, Yara Saber, Dania Abdallah, Abdul Rahman Bizri, Mohamed H Sayegh

PLOS ONE · 2024

DOI: 10.1371/journal.pone.0306457 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Rima Moghnieh und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Department of Internal Medicine, Lebanese American University Medical Center-Rizk Hospital, Beirut, Lebanon. Hauptthemen laut MEDLINE: COVID-19, COVID-19 Vaccines, SARS-CoV-2, Hospitalization. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In this study, we conducted a case-control investigation to assess the immunogenicity and effectiveness of primary and first booster homologous and heterologous COVID-19 vaccination regimens against infection and hospitalization, targeting variants circulating in Lebanon during 2021–2022. The study population comprised active Lebanese military personnel between February 2021 and September 2022. Vaccine effectiveness (VE) against laboratory-confirmed SARS-CoV-2 infection and associated hospitalization was retrospectively determined during different variant-predominant periods using a case-control study design. Vaccines developed by Sinopharm, Pfizer, and AstraZeneca as well as Sputnik V were analyzed. Prospective assessment of humoral immune response, which was measured based on the SARS-CoV-2 antispike receptor binding domain IgG titer, was performed post vaccination at various time points, focusing on Sinopharm and Pfizer vaccines. Statistical analyses were performed using IBM SPSS and GraphPad Prism. COVID-19 VE remained consistently high before the emergence of the Omicron variant, with lower estimates during the Delta wave than those during the Alpha wave for primary vaccination schemes. However, vaccines continued to offer significant protection against infection. VE estimates consistently decreased for the Omicron variant across post-vaccination timeframes and schemes. VE against hospitalization declined over time and was influenced by the variant. No breakthrough infections progressed to critical or fatal COVID-19. Immunogenicity analysis revealed that the homologous Pfizer regimen elicited a stronger humoral response than Sinopharm, while a heterologous Sinopharm/Pfizer regimen yielded comparable results to the Pfizer regimen. Over time, both Sinopharm’s and Pfizer’s primary vaccination schemes exhibited decreased humoral immunity titers, with Pfizer being a more effective booster than Sinopharm. This study, focusing on healthy young adults, provides insights into VE during different pandemic waves. Continuous research and monitoring are essential for understanding vaccine-mediated immune responses under evolving circumstances.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19COVID-19 VaccinesSARS-CoV-2HospitalizationImmunization, SecondaryHumansLebanonMaleAdultFemaleCase-Control StudiesVaccine EfficacyAntibodies, ViralImmunogenicity, VaccineMilitary PersonnelYoung AdultRetrospective StudiesVaccinationImmunity, Humoral

Substanzen

COVID-19 VaccinesAntibodies, Viral

Autor:innen und Institutionen

  • Division of Infectious Diseases, Department of Internal Medicine, Lebanese American University Medical Center-Rizk Hospital, Beirut, Lebanon.
  • Department of Internal Medicine, Central Military Hospital, Military Healthcare, Lebanese Army, Beirut, Lebanon.
  • Head of Laboratory Department, FMPS Holding S.A.L., Beirut, Lebanon.
  • Nursing Office, Makassed General Hospital, Beirut, Lebanon.
  • Gilbert and Rose-Marie Chagoury School of Medicine, Lebanese American University, Byblos, Lebanon.
  • Laboratory Department, FMPS Holding S.A.L., Beirut, Lebanon.

ORCID-Profile: Rima Moghnieh

Zitieren

APA

Moghnieh, R., Haddad, W., Jbeily, N., El-Hassan, S., Eid, S., Baba, H., Sily, M., Saber, Y., Abdallah, D., Bizri, A. R., & Sayegh, M. H. (2024). Immunogenicity and real-world effectiveness of COVID-19 vaccines in Lebanon: Insights from primary and booster schemes, variants, infections, and hospitalization. PLOS ONE. https://doi.org/10.1371/journal.pone.0306457

Vancouver

Moghnieh R, Haddad W, Jbeily N, El-Hassan S, Eid S, Baba H, et al. Immunogenicity and real-world effectiveness of COVID-19 vaccines in Lebanon: Insights from primary and booster schemes, variants, infections, and hospitalization. PLOS ONE. 2024. doi:10.1371/journal.pone.0306457

BibTeX
@article{Moghnieh2024,
  author = {Moghnieh, Rima and Haddad, Wajdi and Jbeily, Nayla and El-Hassan, Salam and Eid, Shadi and Baba, Hicham and Sily, Marilyne and Saber, Yara and Abdallah, Dania and Bizri, Abdul Rahman and Sayegh, Mohamed H},
  title = {Immunogenicity and real-world effectiveness of COVID-19 vaccines in Lebanon: Insights from primary and booster schemes, variants, infections, and hospitalization},
  journal = {PLOS ONE},
  year = {2024},
  doi = {10.1371/journal.pone.0306457}
}
Kostenlos starten →